| Name |
17-DMAG, Hydrochloride Salt
|
| Supplier |
Biorbyt
|
| Catalog |
orb61016
|
| Prices |
$289.00, $323.00, $595.00, $689.00, $1,173.00, $1,819.00, $3,162.00, $4,590.00
|
| Sizes |
25 mg, 100 mg, 250 mg, 500 mg, 1 g, 2 g, 5 g, 10 g
|
| Cas Number |
[467214-21-7]
|
| Pubchem |
9852573
|
| Chemical Name |
[(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl]carbamate;hydrochloride
|
| Formula |
C32H48N4O8•HCl
|
| Molecular Weight |
653.21 g/mol
|
| Purity |
>99% pure
|
| Description |
17-DMAG (Alvespimycin, KOS-1022, NSC 707545) is a potent HSP90 inhibitor with IC50 of 62 nM. A Phase I study of 17-DMAG in treating patients with an advanced solid tumor or lymphoma has been completed.A Phase I study of the combination of intravenous 17-DMAG, Trastuzumab with or without Paclitaxel in patients with advanced solid tumor malignancies or Her2 positive metastatic breast cancer who have previously failed frastuzumab therapy has been completed. 17-DMAG is a synthetic derivative of the antibiotic Geldanamycin with lower hepatotoxicity than the parent antibiotic and higher potency and availability than the similar derivative 17-AAG.
|
| Supplier Page |
Shop
|
